Kajal Patel
Adult Health · Portage, INNPI 1124792551
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$455
- Actelion Pharmaceuticals US, Inc.$451
- Bayer$440
- Novo Nordisk$425
- Boehringer Ingelheim$374
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,48398%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,132 |
| Regeneron Healthcare Solutions, Inc. | 26 | $455 |
| Actelion Pharmaceuticals US, Inc. | 17 | $451 |
| Bayer | 21 | $440 |
| Novo Nordisk | 28 | $425 |
| Boehringer Ingelheim | 25 | $374 |
| GSK | 29 | $365 |
| Lilly USA, LLC | 12 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $265 |
| Shionogi Inc | 9 | $230 |
| Mylan Specialty L.p. | 11 | $213 |
| United Therapeutics Corporation | 3 | $162 |
| Sanofi | 7 | $141 |
| ANI Pharmaceuticals, Inc. | 5 | $135 |
| Baxter Healthcare | 5 | $115 |
| Johnson & Johnson | 1 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 6 | $94 |
| Inspire Medical Systems, Inc. | 3 | $89 |
| Dexcom, Inc. | 6 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Philips North America LLC | 5 | $81 |
| Currax Pharmaceuticals LLC | 5 | $80 |
| Pfizer | 3 | $70 |
| Grifols USA, LLC | 4 | $67 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| Merck | 2 | $57 |
| Itamar Medical Inc | 2 | $57 |
| Mayne Pharma Commercial LLC | 2 | $50 |
| Amgen | 2 | $42 |
| IBSA Pharma Inc. | 2 | $36 |
| Pulmonx Corporation | 1 | $35 |
| Exact Sciences | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Pear Therapeutics (US), Inc. | 1 | $15 |
| Biogen | 1 | $15 |
| Viatris Specialty LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,583 in reported general payments places this provider in the 90th percentile of 391 adult health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 51 | $130,328 |
| JardianceEmpagliflozin | 47 | $79,193 |
| OzempicSemaglutide | 46 | $73,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $72,306 |
| FarxigaDapagliflozin Propanediol | 36 | $55,531 |
| MounjaroTirzepatide | 18 | $38,640 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $29,319 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $24,361 |
| XareltoRivaroxaban | 26 | $16,789 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $15,168 |
| EliquisApixaban | 14 | $13,027 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $8,295 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $6,960 |
| Roflumilast | 29 | $6,114 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $425 | $203,58597 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $374 | $94,36067 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,132 | $84,84962 claims |
| GSKTrelegy Ellipta | $365 | $72,30654 claims |
| Lilly USA, LLCMounjaro | $314 | $38,64018 claims |
| Johnson & JohnsonXarelto | $114 | $16,78926 claims |
| PfizerEliquis | $70 | $13,02714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 adult health providers in Indiana.
Other adult health in Portage
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
- Vincent SmithMerrillville$13K
- Lisa DankoCrown Point$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.